Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

Aspergillus, a potentially deadly fungus, is expanding its reach due to climate change, posing a significant threat to public ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...

Learn when your cough signals serious health problems beyond a cold. Duration, sound, and symptoms reveal hidden dangers.

Sleep Apnea is characterized by several key symptoms that can significantly impact on your quality of life. The most ...

The placement places Ohio behind its neighboring states, Pennsylvania (11th) and Michigan (12th). Pennsylvania was ranked 11th for health care quality, eighth for health care access and 24th for ...

Smoking hurts fertility. It affects hormones and egg quality. Women who smoke face higher infertility risk. Nicotine disrupts ...

PARIS, France and TARRYTOWN, NY, USA I May 30, 2025 I The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic ...

Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in modera ...